期刊文献+

乳腺癌靶向药物静脉输注规范专家共识 被引量:6

原文传递
导出
摘要 乳腺癌患者中约20%~30%人表皮生长因子受体2(HER2)阳性,该类型乳腺癌恶性程度高,侵袭性强,预后差。抗HER2靶向药物能有效降低这种类型乳腺癌患者复发和转移的风险,延长其生存率,改善预后。随着越来越多的新型靶向抗乳腺肿瘤药物陆续在国内上市,对医护人员临床操作技能有了更高的要求。要求医护人员能熟练掌握静脉输注药物的剂量、浓度、配制、贮藏、给药方法和用药的时间等操作流程,做到按时、准确给药。给药同时,医护人员还需要对患者进行药物健康宣教等。因此,为了更好地规范靶向药物的静脉输注管理,使更多患者获益,中国医药教育协会乳腺癌个案管理师分会专家组成员以曲妥珠单抗(赫赛汀)、帕妥珠单抗(帕捷特)、恩美曲妥珠单抗(赫赛莱)3种靶向药物为例,讨论制定了《乳腺癌靶向药物静脉输注规范专家共识》,旨在规范广大基层医院的医护人员乳腺癌靶向药物输注的操作标准。
出处 《中华医学杂志》 CAS CSCD 北大核心 2021年第16期1143-1148,共6页 National Medical Journal of China
  • 相关文献

参考文献9

二级参考文献108

  • 1王涛,江泽飞,宋三泰,刘晓晴,于静新,刘芳,闫敏.单药赫赛汀~治疗复发转移性乳腺癌[J].中华肿瘤杂志,2004,26(7):430-432. 被引量:25
  • 2王莉萍,沈坤炜,沈镇宙.赫赛汀在乳腺癌新辅助治疗与辅助治疗中的新进展[J].中华肿瘤杂志,2006,28(4):241-243. 被引量:26
  • 3RODRIGUES M J, WASSERMANN J, ALBIGES-SAUVIN L, et al. Treatment of node-negative infra-centimetric Her-2+ invasive breast carcinomas: a joint AERIO/REMAGUS study [ J ] . Proc Am Soc Clin Oncol, 2009, 270: 517. 被引量:1
  • 4BUZDAR A U, VALERO V, IBRAHIM N K, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubiciu, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen [ J ] . Clin Cancer Res, 2007, 13(1): 228-233. 被引量:1
  • 5GIANNI L, EIERMANN W, SEMIGLAZOV V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with Her-2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel Her-2-negative cohort [ J ] . Lancet,2010, 375(9712): 377-384. 被引量:1
  • 6UNTCH M, LOIBL S, BISCHOFF J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthraeycline- taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [ J ] .Laneet Oneol, 2012, 13(2): 135-144. 被引量:1
  • 7SLAMON D J, CLARK G M, WONG S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene [ J ] . Science, 1987, 235: 177- 182. 被引量:1
  • 8FERRETTI G, FABI A, FELICI A, et al. Improved prognosis by trastuzumab of women with Her-2-positive breast cancer compared with those with Her-2-negative disease [ J ] . J Clin Oncol, 2010, 28(20): 337. 被引量:1
  • 9WOLFF A C, HAMMOND M E, SCHWARTZ J N, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer [ J ] . J Clin Oncol, 2007, 25: 118-147. 被引量:1
  • 10FABI A, DI BENEDETTO A, METRO G, et al. Her-2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care [ J ] . Clin Cancer Res, 2011, 17(7): 2055-2064. 被引量:1

共引文献162

同被引文献58

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部